The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1490
Isavuconazonium Sulfate (Cresemba) - A New Antifungal
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved isavuconazonium sulfate (Cresemba – Astellas) for intravenous and oral treatment of invasive aspergillosis and invasive mucormycosis in adults. Isavuconazonium sulfate is a prodrug of isavuconazole, a broad-spectrum triazole antifungal.

STANDARD TREATMENT — Voriconazole (Vfend, and generics) is the preferred treatment for invasive aspergillosis. Some experts recommend addition of an echinocandin (see Table 2), but the role of combination therapy for initial treatment has not been well established.1 A lipid formulation of amphotericin B (AmBisome, Abelcet) is generally used in patients who cannot tolerate voriconazole. Patients who do not respond to monotherapy are usually treated with an echinocandin in addition to voriconazole or a lipid formulation of amphotericin B. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Isavuconazonium Sulfate (Cresemba) - A New Antifungal
Article code: 1490d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian